ObsEva (NASDAQ:OBSV) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of ObsEva (NASDAQ:OBSV) in a report published on Thursday morning. The firm issued a hold rating on the stock.

ObsEva Price Performance

The stock has a market cap of $7.94 million, a PE ratio of -0.11 and a beta of 0.68. ObsEva has a 12 month low of $0.08 and a 12 month high of $2.14.

ObsEva Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.